1. Live attenuated vaccine comprising a replication-competent arterivirus, characterized in that said virus has a reduced DUB / deISGiliruyuschey activity due to a mutation in the PLP2-domain of nonstructural protein nsp2 and a pharmaceutically acceptable nositel.2. according to claim Live attenuated vaccine. 1, characterized in that the virus has a mutation in at least two different regions of the consensus position selected from the group consisting of the consensus regions position 296-297, 303-306, 309-319, 326-330 and 343-355 in accordance with EAV-numbering as shown in FIG. 3.3. Live attenuated vaccine according to claim. 1, characterized in that the virus has a mutation in at least 3 different areas consensus position of said group of areas polozheniy.4 consensus. Live attenuated vaccine according to claim. 1, characterized in that the virus has a mutation in one or more of the consensus positions T312, I313 and I353 in accordance with EAV-numbering as shown in FIG. 3, and a pharmaceutically acceptable nositelem.5. according to claim Live attenuated vaccine. 1, characterized in that said arterivirus viruses selected from the group consisting of horses arteritis virus (EAV) of the virus and porcine reproductive and respiratory syndrome (PRRSV) .6. The live vaccine of claim. 2 or 3, characterized in that the mutation in the PLP2-domain consensus regions are in positions 296-297, 303-306, 310-318, 327-329 or 343-354 according to the numbering of EAV-like It is shown in FIG. 3.7. claim a live vaccine. 6, characterized in that said mutation in PLP2-domain are in the areas of consensus positions 296-297, 303-306, 311 -317, 328, 343- 346, 347-348 and 350-353 in accordance with the EAV-numbering as shown in FIG. 3.8. The live vaccine of claim. 7, characterized in that said mutation in the PLP2-domain represent mutations in consensus positions T312, I313 or I353.9. claim a live vaccine. 8, wherein the1. Живая аттенюированная вакцина, содержащая репликацие-компетентный
